JPRN-UMIN000010525已完成未知
Efficacy and safety of erlotinib in elderly patients with non-small-cell lung cancer harboring epidermal growth factor receptor mutations: A phase 2 study. - Efficacy and safety of erlotinib in elderly patients with EGFR-mutations-positive NSCLC.
Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine0 个研究点目标入组 30 人开始时间: 2013年4月17日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 75years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Exclusion criteria are as follows 1: History of severe allergic reactions to drugs. 2: Pregnancy or lactation. 3: Willing to get pregnant. 4: Interstitial lung disease. 5: Severe infection. 6; Severe and unstable medical comorbidities. 7: Difficulty in ingestion. 8: Uncontrolled brain metastases. 9: EGFR T790M mutation. 10: Judgment to attending physician.
研究者
相似试验
招募中
不适用
Efficacy and safety of erlotinib in elderly patients with non-small-cell lung cancer harboring epidermal growth factor receptor mutationsnon-small-cell lung cancerJPRN-UMIN000012056Shimane university hospital38
已完成
不适用
Efficacy and safety of erlotinib in elderly patients with non-small-cell lung cancer without epidermal growth factor receptor mutations: A phase 2 trial.JPRN-UMIN000010526Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine42
已完成
2 期
A phase II study of Erlotinib for elderly patients previously treated non-small cell lung cancer without epidermal growth factor receptor mutationon-small cell lung cancerJPRN-UMIN000004561Fukushima Medical University, cancer center44
已完成
2 期
Phase II study of erlotinib monotherapy for elderly patients with untreated advanced non-small cell lung cancer, 75 years-old or older, and positive EGFR mutation status (OSAKA-LCSG1303)non-small cell lung cancerJPRN-UMIN000011472OSAKA-LCSG31
已完成
2 期
PhaseII trial of erlotinib for elderly patients with advanced or recurrent non-small cell lung cancerJPRN-UMIN000001873Keio University School of Medicine Division of Pulmonary Medicine40